This recent study looked at the available data on cancer treatment outcomes for new cancer therapies approved by the FDA. It found 92 new FDA-approved cancer therapies for 100 indications over 17 years (between 2000 and 2016). About half (44 of 100) of the indications received FDA approval without supporting evidence from randomized clinical trials and the median absolute increase in overall survival was only 2 months. Yes, you’re reading that correctly. And when you consider the cost of these drugs, it’s even more outrageous. If you’ve been struggling to understand how the United States can spend such a high fraction of its GDP on healthcare, here is the answer.
Comentarios